Evoke Pharma Inc (EVOK) — Cash Flow-to-Debt Ratio
Evoke Pharma Inc (EVOK) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of $-521.96K could theoretically repay 0% of its total liabilities ($12.29 Million) in one year. Explore EVOK cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Evoke Pharma Inc Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Evoke Pharma Inc across 14 annual periods. Also explore Evoke Pharma Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Evoke Pharma Inc (2011–2024)
Year-by-year debt coverage analysis for Evoke Pharma Inc. For market capitalisation and broader financial context, see Evoke Pharma Inc (EVOK) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.52x | $-5.46 Million | $10.48 Million | ▼ -0.8% |
| 2023 | -0.52x | $-4.98 Million | $9.65 Million | ▲ +39.2% |
| 2022 | -0.85x | $-6.60 Million | $7.77 Million | ▲ +51.8% |
| 2021 | -1.76x | $-12.35 Million | $7.02 Million | ▼ -235.8% |
| 2020 | -0.52x | $-6.63 Million | $12.65 Million | ▲ +81.7% |
| 2019 | -2.86x | $-5.76 Million | $2.02 Million | ▲ +33.0% |
| 2018 | -4.27x | $-6.98 Million | $1.63 Million | ▼ -182.9% |
| 2017 | -1.51x | $-8.72 Million | $5.78 Million | ▲ +4.6% |
| 2016 | -1.58x | $-8.71 Million | $5.51 Million | ▲ +8.6% |
| 2015 | -1.73x | $-10.50 Million | $6.07 Million | ▲ +8.1% |
| 2014 | -1.88x | $-11.50 Million | $6.11 Million | ▼ -135.4% |
| 2013 | -0.80x | $-3.04 Million | $3.80 Million | ▼ -803.4% |
| 2012 | -0.09x | $-1.75 Million | $19.78 Million | ▲ +43.2% |
| 2011 | -0.16x | $-2.89 Million | $18.56 Million | — |